CN101985483A - Iodinated PRTH, and preparation method and application thereof - Google Patents
Iodinated PRTH, and preparation method and application thereof Download PDFInfo
- Publication number
- CN101985483A CN101985483A CN 201010198151 CN201010198151A CN101985483A CN 101985483 A CN101985483 A CN 101985483A CN 201010198151 CN201010198151 CN 201010198151 CN 201010198151 A CN201010198151 A CN 201010198151A CN 101985483 A CN101985483 A CN 101985483A
- Authority
- CN
- China
- Prior art keywords
- prth
- cancer
- application
- iodinated
- lesion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003126 selective pituitary thyroid hormone resistance Diseases 0.000 title claims abstract description 40
- 101000712600 Homo sapiens Thyroid hormone receptor beta Proteins 0.000 title claims abstract description 19
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 208000019360 selective pituitary resistance to thyroid hormone Diseases 0.000 title claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 32
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 238000003745 diagnosis Methods 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000003902 lesion Effects 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 3
- 229960001479 tosylchloramide sodium Drugs 0.000 claims description 3
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 claims description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 claims description 2
- 238000003805 vibration mixing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 10
- 239000003550 marker Substances 0.000 abstract description 4
- 238000009206 nuclear medicine Methods 0.000 abstract description 4
- 238000013399 early diagnosis Methods 0.000 abstract description 3
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920002302 Nylon 6,6 Polymers 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011362 radionuclide therapy Methods 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- -1 toluene sulfo group acid amides Chemical class 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses iodinated pituitary resistance to thyroid hormone (PRTH), and a preparation method and application thereof, relates to a tumor/cancer diagnosis and treatment reagent, and belongs to the field of medicine and pharmacology. By combining nanotechnology and molecular nuclear medicine, the PRTH is iodinated; and the enhanced permeability and retention (EPR) effect of the PRTH is used for early diagnosis and early treatment of tumor/cancer. The iodinated PRTH has the advantages of simple preparation process, stable marker, safety, no toxicity and good targeting of the tumor/cancer.
Description
Technical field
The present invention relates to a kind of lesion/cancer disease diagnosis, treatment reagent, its preparation method and application belong to the medicine and pharmacology field.
Background technology
Tumour is one of disease of serious harm human health.Annual about 6,000,000 people in the whole world die from malignant tumour, and are every year and increase progressively trend.The non-operative treatment of tumour comprises radiation and chemotherapy, is purpose with the kill tumor cell, but all lacks the specificity to tumour cell.The targeted therapy of tumour is that therapeutic action is optionally concentrated on tumor tissues, tumour cell, oncogene, can reduce to minimum to the untoward reaction of healthy tissues.
Molecular nuclear medicine carries out the live body tomography by advanced persons' such as SPECT, PET, MicroPET, SPECT/CT, PET/CT, MicroPET/CT molecular imaging apparatus to the human or animal, can on molecular level, realize the live body of biological organism physiology, pathological change, real-time, dynamic, noninvasive three-dimensional imaging, have high specific, highly sensitive and high resolving power.For providing information, research specific gene function, biology growing growth, disease development and drug effect effect assessment and pharmacokinetics etc. obtain effective means with analyzing and processing.
Interior radio nuclide therapy method is the characteristic of tumour nuclear medicine, and its action principle is to utilize radiopharmaceuticals that nucleic is passed to diseased tissue.
131I is by the treatment radiopharmaceutical agent of widespread use, and for being used for the treatment of thyroid carcinoma and hyperthyroidism;
123I and
124I is respectively applied for SPECT and PET video picture.
The early diagnosis and therapy that appears as tumour of nanotechnology has brought new hope.Nano material is because its unique physics and chemical property, surface effects, the high surface that micro-dimension effect, quantum effect and structure thereof had, unique photoelectric property, special surface effect and volume effect etc. have broad application prospects it in the research in fields such as environment, biology, medical science.It is modern science (engineering science, biology, physics and chemistry etc.) and modern technologies (microtronics technology, computer technology, high resolution microtechnique, nuclear analytical technology etc.) bonded product.Made a breakthrough at aspects such as the diagnosis of disease and treatments in conjunction with the nanosecond medical science that forms by nanotechnology and medical science, shown powerful growth momentum.
University Of Suzhou discloses a kind of nano-high molecule polymer P RTH, and its structural formula is as follows:
It is the high molecular polymer that has fluorophor and tyrosine group simultaneously, and this polymkeric substance has better biocompatibility, non-immunogenicity, and can modify structure according to different application targets, makes corresponding nanoparticle.Because the rate of permeation that the lymphokinesis of tumor locus is more normally organized is low, in a single day nanometer polymer enters, be difficult to leave by lymphokinesis, but tendency is stranded in tumour cell, be called " strengthen and see through retention effect (the enhanced permeability andretention effect, EPR effect) ".After the mode with intravenously administrable was injected into nanoparticle, nanoparticle can overflow from tumour is misunderstanded each other the endothelial tissue blood vessel that leaks and be trapped in the tumour, thus the retention time of prolong drug in tumour.Utilize the EPR effect, adopt the PRTH nanoparticle can be, thereby reduce side effect, the concentration of raising medicine in tumour chemotherapy and radiotherapy drug targeting tumor tissues.
Summary of the invention
The technical problem to be solved in the present invention is the defective that overcomes existing lesion/cancer disease diagnosis and treatment, treatment technology, and nanotechnology is combined with molecular nuclear medicine, and PRTH is carried out structure of modification, utilizes its EPR effect, is used for the early diagnosis and the treatment of lesion/cancer disease.
In order to solve the problems of the technologies described above, the invention provides following technical scheme:
A kind of I
*-PRTH, for having the compound of following general structure:
In the formula, iodine I
*The expression radionuclide
123I,
124I,
125I,
131Among the I any; 0＜x＜2,3≤y≤4,300≤z≤400.
Above-mentioned I
*The preparation method of-PRTH adopts oxidation style to carry out radioiodination PRTH, and it comprises the steps:
(1) in phosphate buffer, with PRTH and an amount of NaI
*And oxygenant is 10-50 ℃ of vibration mixing down;
(2) add the excessive reductant termination reaction;
(3) reactant uses column chromatography purifying;
In the step (1), the NaI of 20 μ g PRTH and 0.05-10mCi
*Reaction; Described oxygenant is a kind of among chloramine-T, hydrogen peroxide or the Iodogen;
The described reductive agent of step (2) is a kind of in Sulfothiorine, the Sodium Metabisulfite;
The described column chromatography material of step (3) comprises that Sephadex G-10 is to G-100.
Iodate is usually used in mark peptide class, protein and enzyme etc., and its principle is to adopt chemistry or enzymatic oxidn reaction directly will
125I etc. are incorporated into and are labeled in the thing molecule on tyrosine residues or the histamine residue.
With chloramine-T (ch-T) method be example illustrate its iodate principle: ch-T be to toluene sulfo group acid amides N-chlorine derivative sodium salt, in water, easily resolve into the hypochlorous acid of tool oxidisability, it can with
125I
-Be oxidized to positively charged
125I
+, the latter can replace two hydrogen atoms that are labeled in the thing molecule hydroxyl neck position on the tyrosine residues phenyl ring, makes protein or polypeptide by iodate, but adds reductive agent Sodium Metabisulfite stopped reaction.Its iodination reaction process is as follows:
The Ch-T oxidation:
The tyrosine residues mark:
Above-mentioned I
*-PRTH is as the application of lesion/cancer disease diagnosis, medicine, especially as the diagnosis of mammary cancer, liver cancer, lung cancer, thyroid carcinoma, lymphoma, melanoma or intestinal canal tumour, the application of therapeutical agent, or as the application of SPECT or PET diagnostic reagent.Particularly,
123I-PRTH can be used for lesion/cancer disease SPECT video picture,
124I-PRTH can be used for lesion/cancer disease PET video picture,
131I-PRTH both can be used for the SPECT video picture of lesion/cancer disease, can be used for the target radiotherapy of lesion/cancer disease again.
The advantage of the technology of the present invention is:
(1) preparation technology is simple, and marker is stable, is convenient to the further application of clinical, scientific research and drug development;
(2) I
*-PRTH safety non-toxic, good to the target of lesion/cancer disease, have a good application prospect.
Embodiment
Below the preferred embodiments of the present invention are described, should be appreciated that preferred embodiment described herein only is used for description and interpretation the present invention, and be not used in qualification the present invention.
Embodiment 1
1, I
*The preparation of-PRTH:
10 μ l PRTH (2mg/ml) add 7 μ l NaI
*(0.05-10mCi), 20 μ l 0.2mol/L PB (pH8.0), 10 μ l chloramine-Ts (3mg/ml), vortex vibration 30-60s adds 20 μ l Sodium Metabisulfites (6mg/ml), vortex vibration 2-5min termination reaction.The 0.02mol/L PBS (pH7.2 contains 0.3%BSA) that adds 20 μ l in the reaction solution is added to the PD-10 post with 0.02mol/L PBS (pH7.2 contains 0.3%BSA) pre-equilibration behind the mixing, above-mentioned buffer solution elution, and 1ml/min, every pipe 0.5ml collects.
2, I
*The evaluation of-PRTH
Adopt thin-layer chromatography and phosphorus screen imaging system to measure:
(1) thin-layer chromatography: the polyamide 66 film is a upholder, and developping agent is 70% ethanol.Wait behind the point sample to launch to finish, polyamide layer is cut into 10 sections, γ-calculating instrument is measured each section radiocounting, I
*-PRTH marker is at the Rf=0.7-0.9 place, and impurity such as free-iodine are at Rf≤0.1 place.
(2) phosphorus screen imaging system: the polyamide 66 film is a upholder, and developping agent is 70% ethanol.Wait behind the point sample to launch to finish, polyamide layer is observed with phosphorus screen imaging system.The result shows: I
*-PRTH marker is at the Rf=0.7-0.9 place, and free-iodine is at Rf≤0.1 place.
3, I
*The cellular uptake of-PRTH
Collect normal liver cell L-02 and liver cancer cell 7402,10
6Individual/pipe, add
131I-PRTH, 37 ℃ of water-bath 1h, the centrifugal 10min of 2000rpm removes supernatant, and precipitation is surveyed cpm.The result shows: 7402 pairs of liver cancer cells
131The picked-up height of the picked-up L-02 cell of I-PRTH, explanation
131I-PRTH has target preferably to tumour cell.
4, I
*-PRTH SPECT video picture
Get HepA liver cancer model ICR mouse, intraperitoneal injection of ketamine is behind the anesthesia 10min, in tail vein injection 0.1-0.2mCi
125I-PRTH carried out the SPECT video picture after 20min, 40min, 1h, 2h, 18h, 26h, 50h hour.The result shows: tumor locus shows as high dense poly-, after 1 hour target this than being 5.98.
5, the cellular uptake of PRTH
Collect normal liver cell L-02, liver cancer cell 7402 and melanoma cell HT-144 cell, be taped against in 96 orifice plates 10
4Individual/hole, be positioned over 37 ℃, contain 5%CO
2Spend the night in the incubator.Every hole adds 100 μ g PRTH, washs the change in fluorescence of fluorescence microscope cell 3 times with 0.02mol/L PBS pH7.2 behind 37 ℃ of placement 30min.The result shows: the fluorescence in the normal liver cell L-02 very a little less than, and fluorescence intensity illustrates that apparently higher than normal liver cell PRTH has target picked-up preferably to tumour cell in liver cancer cell 7402 and the melanoma cell HT-144 cell.
It should be noted that at last: the above only is the preferred embodiments of the present invention, be not limited to the present invention, although the present invention is had been described in detail with reference to previous embodiment, for a person skilled in the art, it still can be made amendment to the technical scheme that aforementioned each embodiment put down in writing, and perhaps part technical characterictic wherein is equal to replacement.Within the spirit and principles in the present invention all, any modification of being done, be equal to replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (5)
1. I
*-PRTH, for having the compound of following general structure:
In the formula, iodine I
*The expression radionuclide
123I,
124I,
125I,
131Among the I any; 0＜x＜2,3≤y≤4,300≤z≤400.
2. the preparation method of the described I*-PRTH of claim 1 adopts oxidation style to carry out radioiodination PRTH, and it comprises the steps:
(1) in phosphate buffer, with PRTH and an amount of NaI
*And oxygenant is 10-50 ℃ of vibration mixing down;
(2) add the excessive reductant termination reaction;
(3) reactant uses column chromatography purifying;
In the step (1), the NaI of 20 μ g PRTH and 0.05-10mCi
*Reaction; Described oxygenant is a kind of among chloramine-T, hydrogen peroxide or the Iodogen;
The described reductive agent of step (2) is a kind of in Sulfothiorine, the Sodium Metabisulfite;
The described column chromatography material of step (3) comprises that Sephadex G-10 is to G-100.
3. the described I of claim 1
*-PRTH is as the application of the diagnosis of lesion/cancer disease, medicine.
4. application according to claim 3 is characterized in that: described lesion/cancer disease is mammary cancer, liver cancer, lung cancer, thyroid carcinoma, lymphoma, melanoma or intestinal canal tumour.
5. application according to claim 3 is characterized in that: described I
*-PRTH is as the application of SPECT or PET diagnostic reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010198151 CN101985483A (en) | 2010-06-11 | 2010-06-11 | Iodinated PRTH, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010198151 CN101985483A (en) | 2010-06-11 | 2010-06-11 | Iodinated PRTH, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101985483A true CN101985483A (en) | 2011-03-16 |
Family
ID=43709883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010198151 Pending CN101985483A (en) | 2010-06-11 | 2010-06-11 | Iodinated PRTH, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101985483A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103383392A (en) * | 2012-05-02 | 2013-11-06 | 上海方恩医疗用品有限公司 | Novel iodine solution, preparation method of the novel iodine solution, and use of the novel iodine solution in human squamous epithelial cell mucosa and human squamous epithelial cell mucosa precancerosis staining diagnosis |
| CN105396148A (en) * | 2015-11-26 | 2016-03-16 | 江苏诚品生物科技有限公司 | Esophageal-mucosa staining combination set |
| CN107118198A (en) * | 2017-06-08 | 2017-09-01 | 福州大学 | Have rhodamine B derivative of antitumaous effect and fluorescence property and preparation method thereof concurrently |
| CN111303265A (en) * | 2020-03-24 | 2020-06-19 | 中奥生物医药技术(广州)有限公司 | One kind contains131I-labeled Caerin1.1 polypeptide and application thereof |
-
2010
- 2010-06-11 CN CN 201010198151 patent/CN101985483A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103383392A (en) * | 2012-05-02 | 2013-11-06 | 上海方恩医疗用品有限公司 | Novel iodine solution, preparation method of the novel iodine solution, and use of the novel iodine solution in human squamous epithelial cell mucosa and human squamous epithelial cell mucosa precancerosis staining diagnosis |
| CN105396148A (en) * | 2015-11-26 | 2016-03-16 | 江苏诚品生物科技有限公司 | Esophageal-mucosa staining combination set |
| CN107118198A (en) * | 2017-06-08 | 2017-09-01 | 福州大学 | Have rhodamine B derivative of antitumaous effect and fluorescence property and preparation method thereof concurrently |
| CN107118198B (en) * | 2017-06-08 | 2019-07-09 | 福州大学 | Rhodamine B derivative with both anticancer and fluorescent properties and preparation method thereof |
| CN111303265A (en) * | 2020-03-24 | 2020-06-19 | 中奥生物医药技术(广州)有限公司 | One kind contains131I-labeled Caerin1.1 polypeptide and application thereof |
| CN111303265B (en) * | 2020-03-24 | 2020-10-02 | 中奥生物医药技术(广州)有限公司 | One kind contains131I-labeled Caerin1.1 polypeptide and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2732823T3 (en) | Pet tracer for images of neuroendocrine tumors | |
| Ferreira et al. | Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals | |
| Guo et al. | Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide | |
| CN111467510A (en) | A kind of specific targeting radionuclide label and its preparation method and application | |
| CN104725473A (en) | A [18F]AlF-labeled PET polypeptide probe and its preparation method | |
| Wang et al. | Preclinical evaluation of cationic DOTA-triarginine-lipid conjugates for theranostic liquid brachytherapy | |
| CN101985483A (en) | Iodinated PRTH, and preparation method and application thereof | |
| Qin et al. | Dimeric FAPI with potential for tumor theranostics | |
| CN109705193B (en) | A radiolabeled tEB-TMTP1 compound and its preparation method and application | |
| CN103435684B (en) | 18f-fluorine mark pentapeptide title complex and synthetic method | |
| Xia et al. | Application analysis of 124I-PPMN for enhanced retention in tumors of prostate cancer xenograft mice | |
| CN117624278A (en) | Specific tumor diagnosis probe and imaging agent for targeting heat shock protein 90 | |
| Lee et al. | Therapeutic efficacy evaluation of 111In-VNB-liposome on human colorectal adenocarcinoma HT-29/luc mouse xenografts | |
| CN101143897A (en) | Labeling technique for 99Tcm-His10-AnnexinV labeling compound and application of the same as developer in detecting cell apoptosis | |
| WO2022193038A1 (en) | [18f]alf labeled psma targeting molecular probe and preparation method therefor | |
| Tang et al. | Indium-111 labeled bleomycin for targeting diagnosis and therapy of liver tumor: optimized preparation, biodistribution and SPECT imaging with xenograft models | |
| Csikos et al. | Evaluation of the therapeutic efficacy of 213Bi-labelled DOTA-conjugated alpha-melanocyte stimulating hormone peptide analogues in melanocortin-1 receptor positive preclinical melanoma model | |
| Mirzaei et al. | Development of 68Ga ethyl cysteinate dimer for PET studies | |
| CN107021998B (en) | A positron nuclide-labeled polypeptide for tumor imaging | |
| EP3056221A1 (en) | Spect radionuclide-labeled trimeric cyclic rgd peptide, preparation method thereof and imaging method thereof | |
| CN104262458B (en) | Polypeptide in targeted combination with PSMA (prostate specific membrane antigen) membrane out-region, radionuclide labeled polypeptide and application thereof | |
| CN116199736B (en) | A DOTA-Te-PSMA compound and its application | |
| Xu et al. | Synthesis and preliminary evaluation of 99mTc-spermine as a tumor imaging agent | |
| EP3747874B1 (en) | Sodium saccharin having conjugated ligand, derivatives thereof and process for the preparation thereof | |
| CN104610431A (en) | Polypeptide and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20110316 |